-
摘要: 暴发性心肌炎(FM)是少见的临床综合征,其病因谱广、跨度大,临床表现各异,起病急骤、进展迅速,短时间内出现严重血流动力学障碍、恶性心律失常、心源性休克或多器官功能衰竭,早期病死率高,预后差。本文就FM临床研究新进展进行综述。Abstract: Fulminant myocarditis(FM) is a rare clinical syndrome. FM has a wide spectrum and span of etiology, different clinical manifestations, rapid onset and progress. Severe hemodynamic disorders, malignant arrhythmias, cardiogenic shock or multiple organ failure occurred in a short period of time. FM has high early mortality and poor prognosis. This article reviews the new clinical research of FM.
-
Key words:
- fulminant myocarditis /
- hemodynamics /
- diagnosis /
- treatment
-
-
[1] Kociol RD,Cooper LT,Fang JC,et al.Recognition and initial management of fulminant myocarditis[J].Circulation,2020,141(6):e1-e24.
[2] Ammirati E,Cipriani M,Lilliu M,et al.Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis[J].Circulation,2017,136(6):529-545.
[3] Edin ML,Zeldin DC.An improved protocol for the treatment of fulminant myocarditis[J].Sci China Life Sci,2019,62(3):433-434.
[4] Caforio A,Malipiero G,Marcolongo R,et al.Myocarditis:a clinical overview[J].Curr Cardiol Rep,2017,19(7):63-63.
[5] Veronese G,Ammirati E,Brambatti M,et al.Viral genome search in myocardium of patients with fulminant myocarditis[J].Eur J Heart Fail,2020,22(7):1277-1280.
[6] 中华医学会心血管病学分会精准医学学组,中华心血管病杂志编辑委员会,成人暴发性心肌炎工作组.成人暴发性心肌炎诊断与治疗中国专家共识[J].中华心血管病杂志,2017,45(9):742-752.
[7] Caforio AL,Pankuweit S,Arbustini E,et al.Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].Eur Heart J,2013,34(33):2636-2648.
[8] Mahmood SS,Fradley MG,Cohen JV,et al.Myocarditis in patients treated with immune checkpoint inhibitors[J].J Am Coll Cardiol,2018,71(16):1755-1764.
[9] Moslehi JJ,Salem JE,Sosman JA,et al.Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J].Lancet,2018,391(10124):933.
[10] Johnson DB,Balko JM,Compton ML,et al.Fulminant myocarditis with combination immune checkpoint blockade[J].N Engl J Med,2016,375(18):1749-1755.
[11] 黄磊,解玉泉.免疫检查点抑制剂相关性心肌炎的研究进展[J].临床心血管病杂志,2020,36(5):410-414.
[12] Veronese G,Ammirati E,Cipriani M,et al.Fulminant myocarditis:Characteristics,treatment,and outcomes[J].Anatol J Cardiol,2018,19(4):279-286.
[13] Felker GM,Boehmer JP,Hruban RH,et al.Echocardiographic findings in fulminant and acute myocarditis[J].J Am Coll Cardiol,2000,36(1):227-232.
[14] 刘晓庆,肖秋月,邵国柱,等.磁共振定量技术评价心肌炎患者双室心肌应变功能的初步临床研究[J].临床心血管病杂志,2019,35(6):534-539.
[15] 秦瑾,钱明明,邹远林,等.暴发性1型糖尿病合并急性心肌炎1例[J].临床心血管病杂志,2019,35(5):479-482.
[16] Carter BA.2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology[J].Yearbook of Pathology & Laboratory Medicine,2013,21:129-134.
[17] Moslehi JJ,Brinkley DM,Meijers WC.Fulminant myocarditis:evolving diagnosis,evolving biology,evolving prognosis[J].J Am Coll Cardiol,2019,74(3):312-314.
[18] Ammirati E,Veronese G,Brambatti M,et al.Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction[J].J Am Coll Cardiol,2019,74(3):299-311.
[19] Lieberman EB,Hutchins GM,Herskowitz A,et al.Clinicopathologic description of myocarditis[J].J Am Coll Cardiol,1991,18(7):1617-1626.
[20] Ginsberg F,Parrillo JE.Fulminant myocarditis[J].Crit Care Clin,2013,29(3):465-483.
[21] Li S,Xu S,Li C,et al.A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis:a multiple center study[J].Sci China Life Sci,2019,62(3):369-380.
[22] Maejima Y,Yasu T,Kubo N,et al.Long-term prognosis of fulminant myocarditis rescued by percutaneous cardiopulmonary support device[J].Circ J,2004,68(9):829-833.
[23] 胡大一.提高认识,增强信心,切实降低暴发性心肌炎病死率[J].中华内科杂志,2018,57(8):545-548.
[24] Asaumi Y,Yasuda S,Morii I,et al.Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation[J].Eur Heart J,2005,26(20):2185-2192.
[25] Nakamura T,Ishida K,Taniguchi Y,et al.Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support:a retrospective single-center study[J].J Intensive Care,2015,3(1):5-5.
[26] Inaba O,Satoh Y,Isobe M,et al.Factors and values at admission that predict a fulminant course of acute myocarditis:data from Tokyo CCU network database[J].Heart Vessels,2017,32(8):952-959.
[27] Lorusso R,Centofanti P,Gelsomino S,et al.Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients:a 5-year multi-institutional experience[J].Ann Thorac Surg,2016,101(3):919-926.
[28] Frustaci A,Chimenti C.Immunosuppressive Therapy in Myocarditis[J].Circulation,2014,79(1):4-7.
[29] Brambatti M,Matassini MV,Adler ED,et al.Eosinophilic myocarditis:characteristics,treatment,and outcomes[J].J Am Coll Cardiol,2017,70(19):2363-2375.
[30] Heymans S,Eriksson U,Lehtonen J,et al.The Quest for new approaches in myocarditis and inflammatory cardiomyopathy[J].J Am Coll Cardiol,2016,68(21):2348-2364.
[31] Zhang L,Zlotoff DA,Awadalla M,et al.Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J].Circulation,2020,141(24):2031-2034.
[32] Goland S,Czer LS,Siegel RJ,et al.Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy:series of six patients and review of literature[J].Can J Cardiol,2008,24(7):571-574.
[33] Zhang L,Wei TT,Li Y,et al.Functional metabolomics characterizes a key role for n-acetylneuraminic acid in coronary artery diseases[J].Circulation,2018,137(13):1374-1390.
-
计量
- 文章访问数: 307
- PDF下载数: 133
- 施引文献: 0
下载: